PRAMEF4

Across TCGA pan-cancer cohorts, PRAMEF4 RNA is linked to patient survival in 14 of 34 cancer types, making it the most broadly survival-associated PRAMEF4 data layer compared with 7 for mutation status.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher PRAMEF4 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRAMEF4 expression acts as an unfavorable survival marker.

BLCA, KIRC, and HNSC are the cancer types where PRAMEF4 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Tertile	IV	0.122	0.483	<.001	51	view →
KIRC	DFS	Tertile	IV	0.273	0.633	.004	42	view →
HNSC	OS	Tertile	II,III,IV	0.308	0.617	.014	36	view →
CESC	OS	Tertile	IV	0.091	0.593	<.001	36	view →
SCLC	DFS	Tertile	All	0.274	0.815	.013	18	view →
LAML	DFS	Tertile	All	0.204	0.578	.018	18	view →
MESO	DFS	Tertile	II,III,IV	0.162	0.386	.012	18	view →
KIRP	DFS	Tertile	II,III,IV	0.122	0.626	.032	18	view →
LUSC	OS	Tertile	III,IV	0.279	0.676	.019	18	view →
STAD	DFS	Tertile	IV	0.160	0.402	.044	9	view →
GBM	DFS	Tertile	All	0.082	0.300	.002	9	view →
TGCT	DFS	Quartile	All	0.677	0.887	.008	8	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 14 lineages.

PRAMEF4–BLCA (DFS)

Open the BLCA breakdown →